




APPA (Apocynin and Paeonol) modulates pathological aspects of 1 
human neutrophil function, without supressing antimicrobial ability, 2 
and inhibits TNFα expression and signalling.  3 
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Neutrophils are key players in the pathophysiological process underlying inflammatory 22 
conditions by release of tissue-damaging cytotoxic enzymes, reactive oxygen species (ROS) 23 
and a range of chemokines and cytokines. Here we report on the effects of APPA, and its 24 
constituent components, apocynin (AP) and paeonol (PA) on a number of neutrophil 25 
functions, including effects on TNFα- expression and signalling. Neutrophils were treated with 26 
APPA (10-1000µg/mL) prior to the measurement of cell functions, including ROS production, 27 
chemotaxis, apoptosis and surface receptor expression. Expression levels of several key genes 28 
and proteins were measured after incubation with APPA and the chromatin re-modelling 29 
agent, R848. APPA did not significantly affect phagocytosis, bacterial killing or expression of 30 
surface receptors, while chemotactic migration was affected only at the highest 31 
concentrations. However, APPA down-regulated neutrophil degranulation and ROS levels, 32 
and decreased the formation of neutrophil extracellular traps. APPA also decreased cytokine-33 
stimulated gene expression, inhibiting both TNFα- and GM-CSF-induced cell signalling. APPA 34 
was as effective as infliximab in down-regulating chemokine and IL-6 expression following 35 
incubation with R848.  Whilst APPA does not interfere with neutrophil host defence against 36 
infections, it does inhibit neutrophil degranulation, and cytokine-driven signalling pathways 37 
(e.g. autocrine signalling and NF-κB activation), processes that are associated with 38 
inflammation. These observations may explain the mechanisms by which APPA exerts anti-39 
inflammatory effects and suggests a potential therapeutic role in inflammatory diseases in 40 
which neutrophils and TNFα signalling are important in pathology, such as rheumatoid 41 
arthritis. 42 
 43 






Advances in identifying the pathophysiological processes underlying rheumatoid arthritis (RA) 46 
have led to the development of targeted therapies and enhanced outcomes for many patients 47 
(Nikiphorou et al. 2017). However, no single drug is effective for all patients and each is 48 
associated with significant risks of adverse effects demonstrating a need for novel, safe and 49 
effective therapies. A greater understanding of neutrophil biology has led to an appreciation 50 
that these cells play a significant role in rheumatoid arthritis (RA) and other inflammatory 51 
conditions (Wright et al. 2014), but targeting neutrophils therapeutically is challenging, as 52 
host defence must not be compromised. Neutrophils contribute to inflammatory diseases via 53 
the release of cytokines, chemokines, reactive oxygen species (ROS) and proteases (Jaillon et 54 
al. 2013) that are activated via distinct but sometimes overlapping agonist:signal transduction 55 
pathways. Targeting neutrophils in inflammatory diseases must therefore block tissue-56 
damaging processes (e.g. secretion) but not interfere with opsono-phagocytosis or microbial 57 
killing.  58 
 59 
TNFa is a key molecule in the pathology of RA and therapeutic targeting of this molecule, e.g. 60 
with biologics such as TNFi, can lead to dramatic improvements in many, but not all patients 61 
(Hyrich et. 2006; Emery et al. 2014).  Neutrophils contribute to abnormal TNFa signalling in 62 
RA, by both responding to and expressing this cytokine during active disease (Wright et al. 63 
2010). Membrane bound (m)TNFa is elevated on the surface of blood neutrophils in RA 64 
patients with active disease, and NF-kB activation levels (which may be triggered via TNFa 65 
signalling) are elevated, but both surface mTNFa levels and NF-kB activation levels return to 66 
healthy control levels during successful TNFi therapy (Wright et al. 2010). NF-kB is a key 67 





osteoarthritis (OA) (Pilichou et al. 2008). It regulates the functions of all cell types involved in 69 
joint physiology and pathology, including synoviocytes, chondrocytes, osteocytes, endothelial 70 
cells, vascular smooth muscle cells, fibroblasts and leukocytes (Bonizzi and Karin 2004) and so 71 
targeting its over-activity may be beneficial in such diseases (Gilmore and Herscovitch 2006). 72 
This transcription factor plays a central role in the regulation of a number of neutrophil 73 
functions, and it is constitutively activated in many patients with active RA (Muller-Ladner et 74 
al. 2002), likely via TNFα signalling (Kanbe et al. 2008). More recently, a new mechanism of 75 
gene activation in neutrophils involving either endogenously-expressed or exogenously-76 
added TNFα has been identified following incubation of neutrophils with the TLR8 77 
agonist/chromatin remodelling agent, R848 (Zimmerman et al. 2015).  Human neutrophils do 78 
not normally express IL-6 because the promoter region of this gene is transcriptionally “silent” 79 
and in an inactive configuration. However, R848 alters chromatin structure at this locus to 80 
enable its transcription. Both endogenously-expressed and exogenously-added TNFα are 81 
required for this IL-6 expression by prolonging the synthesis of IκBζ co-activator and 82 
sustaining C/EBPβ recruitment and histone acetylation at IL-6 regulatory regions 83 
(Zimmerman et al. 2015). In view of the importance of IL-6 and TNFa in the pathology of 84 
RA, this mechanism of endogenously-expressed TNFa on expression of IL-6 on re-modelled 85 
chromatin could be extremely important in understanding disease mechanisms. Targetting 86 
these processes could have therapeutic benefits.  87 
 88 
APPA, a synthetic combination of two anti-inflammatory molecules, apocynin (AP) and 89 
paeonol (PA), has shown efficacy in canine models of OA (Glasson and Larkins 2012; Larkins 90 
and King 2017A; Larkins and King 2017B) and is currently under clinical development for use 91 





transcription factor, NF-kB as well as other signalling pathways (Muller-Ladner et al. 2002). 93 
AP is a strong ROS scavenger (Nam et al. 2014; Stefanska and Pawliczak 2008; Impellizzeri et 94 
al. 2011A) and inhibits the expression and release of several inflammatory cytokines and 95 
matrix metalloproteinases, while PA, an isomer of apocynin, down-regulates activation, 96 
nuclear translocation, and DNA binding of NF-kB (Su et al. 2010). These combined activities 97 
of APPA inhibit many of the molecular events triggered during inflammatory activation. 98 
However, the effects of APPA and its constituent components on neutrophil function, many 99 
of which are regulated by TNFα, are completely unknown. Given the proposed mechanism of 100 
actions of this drug, it might be predicted to down-regulate inflammatory responses in 101 
neutrophils that are regulated by NF-kB. The aims of this research were to investigate the 102 
effects of APPA, PA and AP on neutrophils in vitro, especially on functions that regulate host 103 
defence against infections. We also investigated the ability of these molecules to modulate 104 
R848-induced IL-6 expression via inhibition of endogenous TNFa activity and show that it is 105 
as effective as TNFa-blocking antibodies in this action. 106 
 107 
Materials and Methods  108 
Isolation of neutrophils  109 
Blood was collected into lithium-heparin vacutainers from healthy controls, after giving 110 
informed consent: this study was approved by the NHS Health Research Authority 111 
(Inflammatory Signalling Pathways; Ref 11/NW/0206: IRAS project ID 75388). Neutrophils 112 
were isolated following sedimentation in HetaSep and centrifugation on Ficoll-paque (Wright 113 
et al. 2016): contaminating erythrocytes were removed by hypotonic lysis. Neutrophils were 114 
examined for purity by Romanowsky staining and microscopic analysis of cytospins, and 115 





cells. Neutrophils were incubated at 106 or 5x106 cells/mL (as described in the text) in RPMI 117 
media (Thermo-Fisher) plus 10% human AB serum (Sigma) and incubated at 37°C and 5% CO2 118 
for up to 20h. Cytokines were added as follows: IL-8 (100ng/mL, Sigma); GM-CSF (5ng/mL, 119 
Roche); TNFα (10ng/mL, Merck); IL-1β (10ng/mL, Source Bioscience); IFNγ (10ng/mL, Source 120 
Bioscience). R848 (Sigma) was used at a concentration of 5µM (Zimmerman et al. 2015).  APPA 121 
(a 2:7 ratio of AP:PA) was dissolved in DMSO and was initially tested over a concentration 122 
range of 10-1000µg/mL (final concs). AP and PA were also used individually at the 123 
concentrations equivalent in the APPA mixture used at 100µg/mL. 124 
Measurement of apoptosis  125 
Neutrophils (1x105) were removed from culture (at the indicated times), diluted with 100μL 126 
of HBSS (Thermo-Fisher) containing 0.5μL annexin V-FITC (Thermo-Fisher), and incubated in 127 
the dark at room temperature for 15min.  The total volume was then made up to 500μL with 128 
HBSS, and propidium-iodide added (final concentration 1μg/mL, Sigma) before analysis 129 
immediately on a Dako Cyan ADP flow cytometer. 10,000 events/sample were analysed. 130 
Degranulation  131 
Neutrophils (5x106/mL) were pre-incubated for 10min with APPA (100µg/mL), before priming 132 
with GM-CSF (5ng/mL) for 30 min and then stimulated to degranulate with cytochalasin B 133 
(5µg/mL) plus fMLP (1µM, both from Sigma) for 15min. Cells were pelleted gently, washed 134 
and analysed by flow cytometry, while supernatants were removed for SDS-PAGE after adding 135 
concentrated Laemmli protein sample buffer. After electrophoresis, proteins were 136 
transferred to PVDF membranes and probed with antibodies to myeloperoxidase (MPO) (R&D 137 
Systems), lactoferrin (Abcam), MMP9 (R&D Systems) and elastase (Abcam). Secondary 138 





antibodies (1:10,000).  Bound antibodies were detected using the ECL system (Merck)  and 140 
film (Amersham).  141 
Antibody staining and flow cytometry 142 
Antibody staining was carried out on freshly-isolated neutrophils incubated for up to 1h, as 143 
described above.  Neutrophils (1x105) were resuspended in PBS (+0.2% BSA).  Antibody-144 
binding was carried out at 4°C in the dark for 30min with conjugated antibodies added as 145 
follows: CD62L-FITC (R&D systems); CD11b-PE (R&D systems); CD16-PE (R&D systems); CD18-146 
PE (R&D systems); CD63-APC (Thermo-Fisher); CD64-FITC (R&D systems); IL-8R (CXCR1)-FITC 147 
(R&D systems); CD66b-FITC (R&D systems); isotype controls (Santa Cruz). Fluorescence was 148 
measured immediately on a Dako Cyan ADP flow cytometer. 10,000 events/sample were 149 
analysed.  150 
Western blotting 151 
Proteins from 5x105 cells, extracted in Laemelli buffer containing protease- and phosphatase-152 
inhibitors, were separated by SDS-PAGE using a 12% gel and transferred onto PVDF 153 
membranes (Merck).  Primary antibodies were: NF-κB (1:1000, Cell Signaling); IκBα (1:1000, 154 
Cell Signaling); Erk1/2 (1:1000, Cell Signaling); p38-MAPK (1:1000, Cell Signaling) and GAPDH 155 
(1:10,000, Abcam). Secondary antibodies were anti-rabbit IgG (GE Healthcare) and anti-156 
mouse IgG (Sigma) HRP-linked antibodies (1:10,000).  Bound antibodies were detected using 157 
the ECL system (Millipore) on carefully exposed film (Merck) to avoid saturation. 158 
Chemotaxis assay 159 
Chemotaxis was performed in 24-well tissue culture plates (coated with 12mg/mL poly-hema 160 
(Sigma)) using hanging cell inserts (Merck) with a 3μm-pore membrane separating media in 161 
the upper and lower chambers.  Standard neutrophil chemotactic agents were added to 162 





both from Sigma). Neutrophils (106) were added to the upper chamber and the plates 164 
incubated for 90min at 37°C and 5% CO2. The number of migrated neutrophils in the lower 165 
chamber after 90min was measured using a Coulter Counter Multisizer3 (Beckman Coulter). 166 
Respiratory burst measurements 167 
Neutrophils (5x106/mL) were pre-incubated for 10min with APPA (10-1000 µg/mL), before 168 
incubation with GM-CSF (5ng/mL) or TNFα (10ng/mL) for 30min.  Cells (5 x 105) were then 169 
added to wells of a 96-well plate and diluted in HBSS containing luminol (10μM) and the 170 
respiratory burst stimulated with fMLP (1μM, Sigma) or PMA (100ng/mL, Sigma). 171 
Luminescence was measured using a Tecan GENios Plus Luminescence plate reader 172 
measuring continuously for 30min. 173 
Opsonisation and Phagocytosis of bacteria 174 
Staphylococcus aureus (Oxford strain) were heat-killed by incubation at 60°C for 30min, 175 
washed twice, and then resuspended in PBS containing 30µM propidium iodide (PI). The 176 
suspension was incubated in the dark at 4°C for 2h and then washed. Opsonization, using 177 
pooled human AB serum from healthy donors (stored in aliquots at -20°C), was achieved by 178 
incubating bacteria (5x108/ml) with 10% heat-inactivated human serum (v/v, final 179 
concentration) for 30min at 37°C before washing. Freshly-isolated neutrophils (106/mL) from 180 
healthy controls were incubated for 30min with PI- labelled, opsonised heat-killed S. aureus 181 
(SAPI) in a ratio of 1:10 and incubated in the dark for 30 min at 37°C with gentle agitation. 182 
Neutrophils were then pelleted by centrifugation, washed twice, and suspended in PBS 183 
containing 5mM EDTA, 3mM sodium azide and 1% paraformaldehyde followed by analysis 184 
using flow cytometry. 185 





Freshly-grown S. aureus were harvested and washed, and suspended at 5x108/ml in HBSS and 187 
opsonised as described above. Freshly-isolated neutrophils (106/mL) were incubated for 1h 188 
at 37°C with gentle agitation with opsonised bacteria at a ratio of 1:10. Neutrophils were then 189 
lysed to release live bacteria by serial dilution in distilled water and vigorous vortexing, before 190 
being plated onto LB agar plates and incubated overnight. Colonies were counted and results 191 
calculated as percentage of bacteria killed compared to bacteria only (no neutrophils) 192 
samples. 193 
NET formation 194 
(a) Quantitation of DNA release: Neutrophils (5 x 105/500µL media containing 2% (v/v) FBS) 195 
were seeded into wells of a 24-well culture and incubated for 1h at 37°C. APPA (100µg/mL) 196 
was then added and incubated for 10min before stimulation with 100nM PMA solution for 3h 197 
at 37°C. After incubation, NET DNA was isolated using Micrococcal nuclease (500mU, Sigma) 198 
and quantified utilizing picogreen (Promega) and a DNA calibration curve. (b) microscopic 199 
visualisation: neutrophils were seeded and incubated as described above. Following 200 
incubation cells were fixed on cover slips, stained with neutrophil elastase antibody and DAPI 201 
(Thermo-Fisher) before being viewed microscopically on a Leica TCS SPE (Papayannopoulos 202 
et al. 2010). 203 
Gene expression using qPCR 204 
1x107 neutrophils (5x106/mL) were pre-incubated for 10min with APPA (10-1000µg/mL), 205 
before incubation with GM-CSF (5ng/mL), TNFα (10ng/mL) or IFNγ (10ng/mL) alone or in 206 
combination for 1h.  Cells were then immediately pelleted and RNA extracted using Trizol 207 
(Thermo-Fisher) and stored at -20oC. RNA was cleaned with RNeasy kit (which included a 208 
DNAse step, Qiagen) before cDNA synthesis, which was amplified using primers for: TNFα 209 





GCTCTCTGCAACCAGTTCTCT, reverse  TGGCTGCTCGTCTCAAAGTAG) AND CCL4 (forward 211 
GCTGTGGTATTCCAAACCAAAAGAA, reverse AGGTGACCTTCCCTGAAGACT). IL-6 was amplified 212 
using a Bio-Rad pre-validated primer pair.  GAPDH was used to normalise samples (forward 213 
CTCAACGACCACTTTGTCAAGCTCA, reverse GGTCTTACTCCTTGGAGGCCATGTG). Results were 214 
quantified by the Pfaffl method and are expressed as fold increase/decrease compared to 215 
untreated neutrophils. 216 
Statistical Analysis  217 





Apoptosis is accelerated by high concentrations of APPA. 223 
In initial experiments, neutrophils were pre-incubated with APPA (10-1000µg/mL) in the 224 
presence or absence (control) of anti-apoptotic cytokines (GM-CSF or TNFα) for 20h. While 225 
both GM-CSF and TNFα delayed neutrophils apoptosis (as described previously (Wright et al. 226 
2014; Wright et al. 2010; Moulding et al. 2001) levels of apoptosis in APPA-treated cells at 227 
20h were slightly increased above untreated (UT) control cells and while this effect was dose-228 
dependent, these effects did not reach statistical-significance (Figure 1A).   APPA had a greater 229 
effect on apoptosis of cytokine-treated neutrophils, and at the highest concentration used 230 
significantly inhibited GM-CSF- and TNFα-delayed apoptosis (p<0.01; Figure 1A).  231 
 232 





Both IL-8 and fMLP are strong neutrophil chemottractants (Figure 1B **p<0.01, *p<0.05, 234 
respectively compared to no stimulus) and were used as positive controls to test the effects 235 
of APPA. Neutrophils were pre-incubated with APPA (10-1000µg/mL) for 10min, before 236 
measurement of chemotaxis for 90min toward IL-8 (100ng/mL, data not shown) or fMLP (0.01 237 
µM, Figure 1B). Chemotaxis towards both IL-8 (not shown) and fMLP in APPA-treated 238 
neutrophils was only inhibited at high concentrations of APPA (500 and 1000µg/mL). 239 
 240 
APPA does not affect the ability of neutrophils to phagocytose and kill bacteria. 241 
Phagocytosis of PI-stained, serum-opsonised S. aureus was largely unaffected (>96% 242 
phagocytosis, compared to untreated control values) by treatment with APPA at all 243 
concentrations used (Figure 1C). Similarly, pre-incubation with APPA (10-1000µg/mL) for 244 
10min did not impair killing of live, serum-opsonised S. aureus, with neutrophils killing ~40% 245 
bacteria over a 60min incubation period at all concentrations tested, which was not 246 
significantly different from untreated controls (Figure 1D). 247 
 248 
APPA does not alter surface receptor expression by neutrophils. 249 
Next, we examined the effect of APPA on expression of receptors that are important in 250 
chemotaxis and phagocytosis. Surface receptor expression of freshly-isolated neutrophils, 251 
and neutrophils incubated for 1h with GM-CSF and TNFα ± APPA (100µg/mL) was measured 252 
by flow cytometry. As previously reported, GM-CSF (Fossati et al. 1998) and TNFα (Lynn et al. 253 
1991) resulted in small increases in expression of CD11b (Figure 1E), but APPA did not affect 254 
this up-regulation. Surface levels of CD18, CD16, CD32, CD64, L-selectin (CD62L) and CXCR1 255 






Effects of APPA on the respiratory burst. 258 
Neutrophils were treated for 10min with APPA (10-1000µg/mL), before priming with GM-CSF 259 
(5ng/mL) for 30min. The respiratory burst was then stimulated via receptor-dependent or 260 
receptor-independent mechanisms with either fMLP (1µM) or PMA (100ng/mL), respectively. 261 
APPA decreased both the the fMLP-stimulated (Figure 2A) and PMA-stimulated ROS levels 262 
(Figure 2B,C) in a dose-dependent manner, with statistically-significant inhibition evident at 263 
10µg/mL. As AP (a constituent of APPA) is a reported scavenger of ROS, we then added APPA 264 
5min after activation of the respiratory burst had been stimulated by PMA. Both 265 
concentrations of APPA used (10µg/mL and 100µg/mL) resulted in an immediate decrease in 266 
the chemiluminescence signal, as would be expected following addition of a ROS scavenging 267 
agent (Figure 2D). For example, the addition of sodium azide (an inhibitor of 268 
myeloperoxidase) decreased ROS levels as rapidly as APPA, whereas the addition of 269 
superoxide dismutase (which catalyses the conversion of O2- into H2O2 and O2) resulted in a a 270 
much slower decline in ROS levels in this experimental system (Figure 2E). Further 271 
experiments utilizing known reactive oxidant scavengers in a cell free system (Figure 2F) 272 
confirmed that ROS quenching/scavenging was largely responsible for the decrease in 273 
chemiluminescence signal by APPA. We then examined the effects of the individual 274 
components of APPA, namely AP and PA for their effects on neutrophil reactive oxidant 275 
scavenging. When these components were added 5min after stimulation of the respiratory 276 
burst by PMA, PA had little effect on levels of reactive oxidants, whereas AP addition resulted 277 
in rapid and extensive quenching (p<0.01), that was equivalent to the quenching effect seen 278 
by APPA (Figure 2G, H).  279 
 280 





The effects of APPA on degranulation was examined. Neutrophils from healthy controls were 282 
pre-incubated for 30min with APPA (100µg/mL) and then primed for 30min with GM-CSF 283 
before stimulating degranulation with fMLP and cytochalasin B. Degranulation of primary 284 
granules, as measured by CD63 expression using flow cytometry (Figure 3A) was decreased in 285 
APPA-treated cells (p<0.05). APPA also inhibited the release of key secretory molecules, 286 
namely MMP9, elastase, MPO and lactoferrin (Figure 3B) as assessed by analysis of cell free 287 
supernatants of stimulated cells by western blotting.  288 
 289 
The generation of neutrophil extracellular traps (NETs) may enhance the trapping and killing 290 
of extracellular pathogens (Carmona-Rivera and Kaplan 2016; Brankz et al. 2014; Smith and 291 
Kaplan 2015; Knight and Kaplan 2012; Grayson and Kaplan 2016), but may also break immune 292 
tolerance by extracellular exposure of autoantigens, thus contributing to autoimmunity 293 
(Thieblemont et al. 2016). PMA stimulated NET production was inhibited by APPA (Figures 294 
4A,B). This inhibition of NET formation was due to the inhibitory effects of AP (p<0.05) in the 295 
APPA mixture, as PA alone had no significant inhibitory effect on PMA-stimulated NET 296 
formation (Figure 4C). 297 
 298 
APPA inhibits key signalling pathways in neutrophils. 299 
Cytokine exposure of neutrophils results in activation of a number of intracellular signalling 300 
cascades that trigger events regulating inflammation. These include ERK1/2 and transcription 301 
factors such as STAT3 and NF-kB, which are dynamically-regulated after exposure of 302 
neutrophils to agents such as GM-CSF, IL-6 and TNFα (Mouzaoui et al. 2014; Wright et al. 303 
2014; McDonald et al. 1997). Neutrophils were incubated in the absence (control) or presence 304 





IL-6 had only minor effects on neutrophil function, it did activate STAT3; GM-CSF activated 306 
STAT3 and pERK phosphorylation; TNFα activated NF-κB (p65 phosphorylation) and enhanced 307 
IkBα turnover (Figure 5A). APPA significantly inhibited IL-6 activation of STAT3 (p=0.03: Figure 308 
5B), GM-CSF activation of Erk 1/2 (p=0.03: Figure 5C) and TNFα-mediated activation of NF-kB 309 
(p=0.008: Figure 5D).  310 
 311 
Effects of APPA on neutrophil gene expression. 312 
In addition to their ability to prime neutrophils, GM-CSF, TNFα and IFNγ can also rapidly 313 
activate neutrophil gene expression. Therefore, we determined if APPA had any effect on the 314 
expression of several key neutrophil genes, particularly those regulated by NF-kB. Neutrophils 315 
from healthy controls were pre-incubated with APPA (100µg/mL) for 10min before 316 
stimulation with cytokines (GM-CSF, TNFα or IFNγ) for 1h. Gene expression was measured 317 
using qPCR to quantify transcripts for TNFα, IL-8 and IL-1β. Expression of Nrf2 was also 318 
measured as this transcription factor regulates the expression of antioxidant proteins that 319 
protect against oxidative stress (Niture et al. 2020; Murakami and Motohashi 2015). Figure 6 320 
shows that cytokine treatment of neutrophils resulted in enhanced expression of IL-1b, 321 
(Figure 6A), IL-8 (Figure 6B), Nrf2 (Figure 6C) and TNFα itself (Figure 6D), and levels of 322 
expression of these genes were greater after TNFα treatment than were observed after 323 
incubation with either GM-CSF or IFNγ. Pre-treatment of neutrophils with APPA (100µg/mL) 324 
for 30 min resulted in down-regulation of TNFα-activated expression of IL-1β, IL-8 and TNFα, 325 
in line with its ability to inhibit NF-kB (Figure 6). However, APPA enhanced TNFα- and GM-326 
CSF-induced expression of Nrf2 suggesting it is able to induce an anti-oxidative stress 327 






The recent discovery that neutrophil chromatin can be re-modelled by agents likely to be 330 
important in inflammation, to enable transcription of normally silent genes (Zimmerman et 331 
al. 2015) has transformed our understanding of the transcriptional repertoire of neutrophils 332 
in disease. We therefore incubated neutrophils with the chromatin re-modelling agent, R848 333 
for 7h and measured the effects of APPA on expression of the chemokines, CCL3 and CCL4, 334 
and the pro-inflammatory cytokine IL-6. Previous work has shown that endogenous TNFα is 335 
important for this R848-induced IL-6 expression (Zimmerman et al. 2015) and so we also 336 
incubated R848-treated neutrophils with the neutralising TNFα antibody, infliximab. R848 337 
stimulated the expression of CCL3, CCL4 and IL-6 under these experimental conditions and 338 
this expression was significantly decreased in cultures co-incubated with infliximab (Figure 7 339 
A-C), confirming the role of endogenous TNFα in this gene expression. When we measured 340 
the effects of the individual componts of APPA on this gene expression, both APPA and AP 341 
significantly decreased expression of IL-6 and CCL3, but PA further decreased expression 342 
levels to unstimulated, control values (Figure 8A,B).  343 
 344 
Discussion 345 
APPA and its constituent components, apocynin (AP) and paeonol (PA), have therapeutic 346 
effects in several inflammatory settings, explained in part by inhibition of the NF-kB signalling 347 
pathway and in part on its ability to scavenge ROS (Glasson and Larkins 2012; Impellizzeri et 348 
al. 2011B; Rigant et al. 2008). APPA is beneficial in canine OA (Glasson and Larkins 2012; 349 
Larkins and King 2017A; Larkins and King 2017B) and may have potential as a therapeutic in 350 
human inflammatory conditions. However, its mechanisms of action and possible effects on 351 
the immune system must be established before it can be considered as a novel therapeutic 352 





key elements of host defence and other relevant functions of human neutrophils. A major 354 
challenge in the design of new anti-inflammatory agents is to balance efficacy with safety, 355 
particularly ensuring that host defence to infection is protected. 356 
 357 
In addition to their role in recognition, uptake and killing of pathogens, human neutrophils 358 
can express a variety of immuno-regulatory molecules such as chemokines, cytokines, growth 359 
factors and angiogenic factors (Wright et al. 2014; Jaillon et al. 2013; Cassatella 1995). These 360 
molecules regulate the function of other immune- and tissue-cells, and their inappropriate 361 
release by neutrophils also plays a role in inflammatory diseases by prolonging or sustaining 362 
inflammatory responses (Cassatella 1995). Many neutrophil functions are regulated by rapid 363 
activation of kinase cascades that control enzyme activity and/or result in changes in the 364 
affinities/surface expression levels of receptors that control opsono-phagocytosis (Cross et al. 365 
2006; Fossati et al. 2002).  These functions do not generally require changes in gene 366 
expression. However, other neutrophil functions, such as expression of certain 367 
chemokines/cytokines require activation of transcription factors, and perhaps chromatin 368 
remodelling, to control de novo gene expression (Wright et al. 2013). 369 
 370 
We show here that APPA has little or no effect on neutrophil functions such as receptor 371 
expression, uptake and killing of osponised bacteria or chemotaxis. Moreover, APPA did not 372 
interfere with cytokine-mediated regulation of these functions under the experimental 373 
conditions employed in this study. Some inhibitory effects of high concentrations of APPA 374 
were noted (≥500µg/mL), but such concentrations are unlikely to be reached therapeutically 375 
(unpublished data, Professor Ian Clark, University of East Anglia). At the lowest concentration 376 





PMA. The assay used to detect these oxidants, namely luminol-enhanced chemiluminescence, 378 
requires the combined activities of the NADPH oxidase and myeloperoxidase (Edwards 1987), 379 
and can be modified experimentally to either measure the production of oxidants or the 380 
scavenging effects of anti-oxidants. We show here that the effects of APPA on ROS production 381 
are largely via its ability to scavenge oxidants, rather than by preventing their generation. In 382 
spite of the fact that the NADPH oxidase is required for the efficient killing of a large spectrum 383 
of micro-organisms (Elson et al. 2006; Zicha et al. 1997), some patients with autosomal 384 
recessive chronic granulomatous disease have decreased (but not absent) NADPH oxidase 385 
activity, and yet do not always have recurrent infections (Liese et al. 1996). Our experiments 386 
described here would support this observation: 10µg/mL APPA significantly scavenged ROS 387 
but did not impair killing of S. aureus. An alternative explanation is that APPA did not access 388 
the phagolysosome at concentrations sufficient to impair killing. It is also important to note 389 
APPA is a scavenger of ROS, rather than an inhibitor of the NADPH oxidase. Therefore, the 390 
ion-pumping activities of the NADPH oxidase, necessary for generating optimal protease 391 
activity within the phagolysosome (Reeves et al. 2002) will be unaffected by APPA and hence 392 
microbial killing can still occur, even though ROS may have been quenched.  Based on these 393 
observations, we conclude that therapeutic doses of APPA are likely to have minimal impact, 394 
if at all, on neutrophil-mediated host defence against infection. 395 
 396 
ROS production by neutrophils may also activate signalling networks such as MAPKs and NF-397 
κB, to regulate expression of molecules such as IL-8, IL-1β and TNFα (Ndengele et al. 2005). 398 
Other groups have shown the importance of the ROS sensitive MAPKs/NF-kB signalling 399 
pathway in the induction of IL-8 in lung epithelial cells (Boots et al. 2012). ERK, STAT3 and NF-400 





of APPA may be mediated through its antioxidant activity and inhibition of ROS-sensitive 402 
inflammatory signalling (Liu et al. 2014). Here we show that APPA interferes with TNFα-403 
mediated activation of NF-kB and GM-CSF activation of Erk1/2.  404 
 405 
It is noteworthy that APPA decreased TNFα-activated expression of IL-8, TNFα itself and IL-406 
1β, although the inhibitory effect on expression of the latter did not reach statistical 407 
significance. APPA was also an effective inhibitor of IL-6, CCL3 and CCL4 expression triggered 408 
by the TLR8 agonist and chromatin re-modelling agent, R848. This agonist triggers the 409 
expression of these genes following chromatin re-modelling via endogenous expression of 410 
TNFα, and we show here that APPA (and AP and PA) were as effective as the therapeutic 411 
agent, infliximab in the inhibition of this autocrine signalling process. This indicates that APPA 412 
could have anti-inflammatory potential, in clinical scenarios in which neutrophils and TNFα-413 
signalling play a significant role in pathology e.g. RA (Wright et al. 2014).  APPA also enhanced 414 
expression of Nrf2, an anti-inflammatory regulator of anti-oxidant proteins that protects 415 
against oxidative stress (Kaspar et al. 2009). Further work is necessary to fully characterise 416 
this phenomenon and determine if APPA regulates the expression of other proteins that 417 
control cellular responses to stress in inflammatory disease. 418 
 419 
Conclusion 420 
We show that whilst APPA has no significant effects on host defence neutrophil functions 421 
such receptor expression, phagocytosis and bacterial killing, it significantly down-regulates 422 
TNFα-mediated expression of cytokines and chemokines by neutrophils. This suggests that 423 





dysregulation of cytokine expression or oxidative stress in inflammatory diseases such as RA, 425 
without suppressing host defence. 426 
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Figure legends 570 
 571 
Fig. 1 Effects of APPA on neutrophil apoptosis, chemotaxis, phagocytosis/killing and 572 
receptor expression. In (A) neutrophils (106/mL) from healthy controls were incubated for 573 
20h in the absence (UT) or presence of APPA (10-1000μg/mL) in the absence (control      ) or 574 
presence of cytokines known to regulate neutrophil apoptosis. Following 10min pre-575 
incubation with APPA, the following additions were made: GM-CSF (5ng/mL,        ) or TNFα 576 
(10ng/mL,        ) and incubation was continued for a further 20h (n=7). In B, neutrophils (106) 577 
from healthy controls were incubated in the absence (UT) or presence of APPA (10-1000 578 
µg/mL) for 10min, then migration towards fMLP (10-8M) or IL-8 (100ng/mL) was measured 579 
after a 90min incubation period. Untreated neutrophils migrating towards fMLP (10-8M) and 580 
IL-8 (100ng/mL) are shown as positive controls (** p<0.01, * p<0.05). Values shown are 581 
means (± SEM, n=4). In C and D, neutrophils were pre-incubated for 10 min with the 582 
indicated concentration of APPA (or DMSO vehicle control). In C they were then incubated 583 
with a 10:1 ratio of PI-stained, heat-killed serum-opsonised S. aureus and phagocytosis was 584 
determined by flow cytometery. Values shown are mean MFI values (normalised to 585 
untreated control values of 100%),  ± SD (n=3). In D, neutrophils  subsequently incubated 586 
with a 10:1 ratio of live, serum-opsonised S.aureus and after 1h incubation, bacterial 587 
viability was determined by plate counting. Values shown are mean values ± SD (n=3).  588 
In E, neutrophils were isolated from healthy controls and expression of cell surface receptors 589 
was measured on freshly-isolated cells by flow cytometry. These levels of expression were 590 
compared with those on neutrophils pre-incubated with APPA (100µg/mL) and stimulated for 591 
1h with either GM-CSF (5ng/mL) or TNFα (10ng/mL), as follows:     No additions;      TNFα only;        592 
        GM-CSF only;      APPA only;     TNFα + APPA;   GM-CSF + APPA. Levels of CD11b, CD18, 593 
CD16, CD32, CD64 and CXCR1 (IL-8R) were measured.  Inset shows effects of APPA with and 594 
without GM-CSF or TNFα on CD62L expression levels. There was no significant difference in 595 
surface marker expression following treatment with APPA. Values shown are means ± SD (n 596 







Fig. 2 APPA decreases ROS production by activated neutrophils. Neutrophils (5x106) from 600 
healthy controls were incubated in the absence (UT) or presence of APPA (10-1000µg/mL) 601 
for 10 min perior to mesurements of luminol-enhanced chemiluminescence. In A APPA-602 
treated neutrophils were then primed for 30min with 5ng/mL GM-CSF before stimulating 603 
with fMLP (1µM), n=3, ** p<0.01, while in B APPA-treated neutrophils were stimulated 604 
using PMA (100ng/mL), n=3, * p<0.01. C shows representative chemiluminescence traces of 605 
PMA-stimulated respiratory burst activity in the absence and presence of increasing 606 
concentrations of APPA: (    ) untreated controls, while      ,      ,       ,      ,        , show APPA 607 
concentrations of 10, 10, 200, 500 and 1000µg/mL, respectively.  In D PMA-induced 608 
respiratory burst activity was stimulated (     ) and after 5min incubation, APPA (at 10µg/mL,     609 
and 100µg/mL:     ) was added as indicated by the arrow. In E PMA was used to stimulate 610 
ROS production by neutrophils. As indicated by the arrow, the following additions were 611 
injected into the cell suspension:     , no additions;     , catalase (2U/mL);     , superoxide 612 
dismutase (40µg/mL);    , sodium azide (1mM);      , APPA (100µg/mL). In F APPA (10-613 
1000µg/mL) or DMSO (as solvent control) were added to a cell-free luminol system utilizing 614 
hydrogen peroxide, as follows:     , no additions;          , DMSO;     , 10µg/mL APPA;      , 615 
100µg/mL APPA;     , 200µg/mL APPA;      , 500µg/mL APPA. representative result of 3 616 
separate experiments.  In G, Neutrophils were stimulated with with PMA (    )  and after 617 
5min incubation APPA (100µg/mL,     ), AP (22µg/mL,      ) or PA (78µg/mL,      ) added, as 618 
indicated by the arrow. H shows replicate data of total chemiluminescence from G, ** p 619 
value < 0.01, n = 11. 620 






Fig. 3 APPA decreases neutrophil degranulation. In (A) and (B), neutrophils (5x106) from 623 
healthy controls were incubated in the absence (UT) or presence of APPA (100µg/mL) for 624 
10min. APPA-treated neutrophils were then primed for 30min with GM-CSF before 625 
stimulating degranulation with fMLP (1µM) plus cytochalasin B (5µg/mL). In (A) neutrophils 626 
were analysed for expression of CD63, a marker of degranulation using flow cytometry (* 627 
p<0.05, n = 7). In B, supernatants from above were collected, proteins separated using SDS-628 
PAGE before western blotting and probed for expression of MMP9, MPO, elastase and 629 
lacioferrin, as indicated.  630 
 631 
Fig. 4 APPA decreases formation of neutrophil extracellular traps (NETs). Neutrophils were 632 
treated with PMA for 4h in the absence and presence of 100µg/mL APPA. NET formation was 633 
measured by DNA release in A (n=4, *p=0.04) and in B by microscopy utilizing dual DAPI and 634 
neutrophil elastase staining. In C, DNA released into NETs was determined after incubation 635 
with PMA in the p[resence of 100µg/mL APPA, 22µg/mL AP and 78µg/mL PA (n=6, **p <0.05).  636 
 637 
Fig. 5 Effects of APPA on activation of cytokine-regulated cell signalling. Neutrophils (5 x 106) 638 
were incubated in the absence (UT) or presence of APPA (100µg/mL) for 10min. APPA-treated 639 
neutrophils were then stimulated for 15min with either IL-6, GM-CSF or TNFα at the 640 
concentrations described in Methods. Western blotting was used to detect activated 641 
(phosphorylated) forms of STAT3, NF-κB, IκBα and Erk1/2. A shows typical blot obtained from 642 
3 separate experiments, while B-D show combined densitometric data (n=3), for IL-6 643 
stimulated STAT3 activation B, GM-CSF-stimulated Erk1/2 activation C and TNF stimulated NF-644 
κB activation, D (* , p=0.03, 0.03 and 0.008, respectively) after normalisation to GAPDH 645 






Fig. 6 APPA down-regulates TNFα-stimulated gene expression but up-regulates expression of 648 
NRF2. Neutrophils (107) from healthy controls were incubated in the absence  (     ) or presence 649 
(     ) of APPA (100µg/mL) for 10min. APPA-treated neutrophils were then stimulated with GM-650 
CSF, IFNγ or TNFα for 1h. qPCR was used to quantify transcript levels of IL-1β (A), IL-8 (B), 651 
NRF2 (C) and TNFα (D). Values shown are mean (± SEM), n=6, * p=0.012. 652 
 653 
Fig. 7 APPA, AP and PA are as effective as infliximab in down-regulating chemokine and 654 
cytokine expression. Neutrophils were incubated with 5µM R848 for 7h in the absence (R848) 655 
or presence of 200µg/mL infliximab (IFX) or 100µg/mL APPA. Expression levels of mRNA for 656 
CCL3 (A), CCL4 (B) and IL-6 (C) (normalised to GAPDH mRNA levels) were then measured by 657 
qPCR. * p < 0.05, ** p = 0.01 (n = 5). In D and E, neutrophils were incubated in the presence 658 
of R848 (5µM), APPA (100µg/mL), Infliximab (IFX, 200µg/mL), AP (22µg/mL) and PA 659 
(78µg/mL). Levels of mRNA for IL-6 (in D) and CCL3 (in E) were measured by qPCR and 660 
normalised to GAPDH mRNA levels. Values shown are means ± SEM (n = 5). * p <0.05. ** 661 
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